Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 1 recruiting now early-phase tilt small index

Oligometastatic Prostate Adenocarcinoma: early-phase trial registry

1 of 1 indexed Oligometastatic Prostate Adenocarcinoma trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #11,370 of 28,707 conditions by registered trial count.

1 US clinical trials · 1 currently recruiting · #11,370 of 28,707 conditions by registered trial count

Oligometastatic Prostate Adenocarcinoma: 1 US clinical trial tracked, 1 recruiting.

Oligometastatic Prostate Adenocarcinoma is the subject of 1 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is Jonsson Comprehensive Cancer Center, running 1 of these trials.

Enrollment posture brief

Registry condition oligometastatic-prostate-adenocarcinoma

OPEN 1 | RECR 100% | LATE 0 | EARLY 1 | RANK #11370 | SPON 1

Nearest open-share peer: Aortic Arch Aneurysm (100% recruiting · 5 trials)

Oligometastatic Prostate (th…100%Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%
Open-enrollment share among volume-matched conditions near Oligometastatic Prostate Adenocarcinoma

Oligometastatic Prostate Adenocarcinoma lists 1 open slots (100% of 1 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Oligometastatic Prostate Adenocarcinoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Oligometastatic Prostate Adenocarcinoma is recruiting above its size-band peers.

    1 of 1 indexed trials (100%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

Phase 21

Phase Distribution

PhaseTrial count
Phase 2 1

Top Sponsors

Named interventions

Most-linked intervention names on Oligometastatic Prostate Adenocarcinoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

PSMA PET-CT Scan Procedure
1 trials
Lutetium Lu 177 Vipivotide Tetraxetan Drug
1 trials
Gallium Ga 68 Gozetotide Other
1 trials
Actinium Ac 225 Vipivotide Tetraxetan Drug
1 trials
Biospecimen Collection Procedure
1 trials

US sites by state

Facility locations filed on Oligometastatic Prostate Adenocarcinoma trials. A trial with sites in several states counts in each.

California 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Oligometastatic Prostate Adenocarcinoma page

1 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Oligometastatic Prostate Adenocarcinoma condition card totals 1 registered trials; most-linked intervention PSMA PET-CT Scan; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.